Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes

CONCLUSIONS: HMA non-persistence, which increased over time, was associated with significantly higher non-HMA-related HRU, and numerically higher AML progression in MDS patients initiating HMAs. Future studies should evaluate predictors of HMA non-persistence in this patient population.PMID:33631084 | DOI:10.1080/16078454.2021.1889161

Source: Hematology - February 25, 2021 Category: Hematology Authors: Wendy Y Cheng Ambika Satija Hoi Ching Cheung Kala Hill Tim Wert Fran çois Laliberté Patrick Lefebvre Source Type: research